Loading
A phase 1/2 trial of Pembrolizumab, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, active and no longer recruiting.
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT04083599 by Genmab, with 350 participants enrolled, started 2019-09-17 and due to reach its primary completion in 2025-12-30. Interventions recorded: GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU. Conditions listed: Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma. No results are recorded here; the registry entry is the source.
Shares Genmab, Cisplatin, Carboplatin, Head and neck squamous cell carcinoma.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Paclitaxel / nab-paclitaxel, Carboplatin, Head and neck squamous cell carcinoma.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Genmab, Head and neck squamous cell carcinoma, Small-cell lung cancer, Colorectal cancer.
Shares Genmab, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Cisplatin, Pembrolizumab, Colorectal cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Pembrolizumab, Colorectal cancer.
Shares Genmab, Paclitaxel / nab-paclitaxel, Gemcitabine, Carboplatin.